Last reviewed · How we verify
Vardenafil Oral Tablet
At a glance
| Generic name | Vardenafil Oral Tablet |
|---|---|
| Also known as | Levitra |
| Sponsor | Respira Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234 (PHASE1)
- Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia (PHASE3)
- BAY38-9456 (Vardenafil HCL Tablet) in ED Treatment for China Registration. (PHASE3)
- BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction (PHASE4)
- A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function (PHASE2)
- Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study (PHASE1)
- The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vardenafil Oral Tablet CI brief — competitive landscape report
- Vardenafil Oral Tablet updates RSS · CI watch RSS
- Respira Therapeutics, Inc. portfolio CI